Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous
A case report

Jeonghun Lee, MD\textsuperscript{a}, Young Joo Lee, MD, PhD\textsuperscript{b}, Youngsun Kim, MD, PhD\textsuperscript{b,*} \(\textsuperscript{a}\) Department of Internal Medicine, Ye Hospital, Anyang, \textsuperscript{b} Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Korea. The patient provided informed consent for publication of this case.

Abstract

**Rationale:** Acute acalculous cholecystitis (AAC) is an extremely rare manifestation of systemic lupus erythematous (SLE). In previous reports, most of the patients were already diagnosed cases of SLE upon confirmation of AAC.

**Patient concerns:** A 24-year-old female who initially presented with fever and acute right upper quadrant abdominal pain. She had no medical history.

**Diagnoses:** Abdominal ultrasonography and computed tomography (CT) showed gallbladder thickening with pericholecystic edema without gallstones or sludge, demonstrating acalculous cholecystitis. She revealed discoid rash on the both shin. Laboratory tests revealed pancytopenia. The titer of antinuclear antibody (ANA) was 1:1280. Anti-dsDNA antibody, anti-phospholipid antibody, anti-Sm antibody test, and proteinuria in 24 hours were positive. Both C3 and C4 were low. Echocardiography and chest CT showed pericardial effusion and pleural effusion. Using the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria, the score was 31. We thought AAC of this case that was one of the initial manifestations of SLE.

**Interventions:** The patient was treated with high-dose prednisolone (1 mg/kg) and hydroxychloroquine 400mg.

**Outcomes:** After 4 days of administration of high-dose corticosteroid therapy, symptoms rapidly improved. After 35 days of the treatment, her symptoms and disease activity of SLE were markedly improved.

**Lessons:** Although AAC being the initial manifestation of SLE is very rare, prompt diagnosis and management with corticosteroids precluded surgical intervention. Physicians need to be cognizant of AAC as a disease flare and as a rare initial manifestation of SLE.

**Abbreviations:** AAC = acute acalculous cholecystitis, ANA = antinuclear antibody, CT = computed tomography, EULAR/ACR = European League Against Rheumatism/American College of Rheumatology, MIVOD = mesenteric inflammatory veno-occlusive disease, SLE = systemic lupus erythematous.

**Keywords:** acute acalculous cholecystitis, corticosteroid, initial manifestation, systemic lupus erythematous

1. Introduction

Most acute acalculous cholecystitis (AAC) occurring in critically ill patients likely exhibit a worse prognosis than acute calculous cholecystitis in immunocompetent individuals. Cholecystectomy is often considered the definitive treatment because of its high morbidity and mortality.\[1\] Most cases of AAC in systemic lupus erythematosus (SLE) developed after the SLE diagnosis. AAC is a very rare initial manifestation in SLE, and it is difficult to recognize that AAC is associated with SLE. Recently, high dose corticosteroid therapy has been a successful treatment regimen in patients with AAC in SLE due to the improvement of symptoms and absence of infection-related complications.\[2\] However, there is no definitive consensus regarding the treatment of AAC in SLE. We report a case of a 24-year-old female with AAC as an initial manifestation of SLE who demonstrated improvement of symptoms and disease activity after administration of high-dose corticosteroid therapy.

2. Case report

This study was approved by the Ethics Committee and Institutional Review Board of the Kyung Hee University Medical Center, Seoul, Korea. The patient provided informed consent for publication of this case.

A 24-year-old female was admitted to our hospital with fever and acute right upper quadrant abdominal pain. The patient had no family history of hepatobiliary disease.

On admission, blood pressure was 130/90 mmHg, body temperature was 38.8 °C, pulse rate was 72/min, and respiratory
rate was 20/min. A discoid rash was noted on both her shins (Fig. 1).

On physical examination, tenderness was appreciated in the right upper quadrant of her abdomen and Murphy’s sign was positive. Laboratory tests revealed pancytopenia (white blood cells 3860/µL, hemoglobin 5.2g/dL, and platelet 107,000/µL) with normal hepatobiliary enzymes (aspartate aminotransferase, 35IU/L; alanine aminotransferase, 11IU/L; total bilirubin, 0.32 mg/dL; gamma-glutamyl transferase, 33IU/L; alkaline phosphatase, 96IU/L; and albumin, 3.0g/dL). Serum creatinine and procalcitonin levels were normal at 0.81mg/dL and 0.24mg/mL, respectively. CRP and ESR were elevated at 65.33mg/dL and >150mm/h, respectively. NT-proBNP level was elevated at 4920 pg/mL. Low complement levels (C3 54mg/dL, C4 5mg/dL) and high antinuclear antibody titer (ANA; 1:1280, homogenous pattern) with positive anti-dsDNA antibody (>98.00IU/mL), anti-phospholipid antibody, and anti-U1-RNP antibody (10.9IU/mL) were revealed. Anti-SSA antibody was positive, but the anti-SSB antibody, anti-Sm antibody, MPO-ANCA and PR3-ANCA, and direct/indirect Coombs were negative. Urine analysis was positive for hematuria and 3+ proteinuria (819mg in 24hours).

Abdominal ultrasonography and CT showed gallbladder thickening with pericholecystic edema without gallstones or sludge, demonstrating acalculous cholecystitis (Fig. 2). Trans-thoracic echocardiography and chest CT showed pericardial effusion and pleural effusion, indicating pericarditis and pleuritis as complications (Fig. 3).

Based on the clinical criteria which include a discoid rash, hair fragility with broken hairs, pleural effusion, pericardial effusion, proteinuria, leukopenia, and thrombocytopenia, and immunologic markers such as positive ANA, anti-dsDNA antibody, antiphospholipid antibody, and low complement levels, she was diagnosed with active SLE, fulfilling 10 points from the Systemic Lupus International Collaborating Clinics 2012 criteria and 31 points from the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria. We surmised that a significant infection was not the precipitating factor because her condition did not deteriorate, and there was no evident increase in procalcitonin values, and the blood culture was rendered negative.

Since previous reports of AAC in SLE were associated with an active disease flare, we considered AAC in this case as one of the manifestations of SLE (SLEDAI-2K 29 points). Therefore, we administered high-dose prednisolone (1mg/kg) and hydroxychloroquine 400mg for the treatment of AAC in SLE. After 4 days of the treatment, the symptoms and laboratory tests were improved. Follow-up CT and ultrasonography were preformed.  

**Figure 1.** The discoid rash revealed irregular disc-shaped, dark erythematous plaques containing hyperkeratosis on shin.

**Figure 2.** Abdominal computed tomography findings. Edematous gall bladder wall thickening without stones.

**Figure 3.** Chest computed tomography findings. Cardiomegaly with pericardial effusion, bilateral pleural effusions, probably loculate, without discernible pleural thickening.
Gallbladder involvement is rare. AAC had an incidence of less than 0.05% as the initial manifestation in patients with SLE.

EULAR/ACR classiﬁcation criteria, the score was 31. All patients were successfully treated.

Table 1

| Case/Reference | Age (years) | Sex | SLEDAI-2k | Treatment | Outcome |
|----------------|-------------|-----|-----------|-----------|---------|
| Yang H, et al ** | 29          | F   | 9         | CS/CTX    | Remission |
|               | 26          | F   | 4         | CS/Ctx    | Remission |
|               | 43          | F   | 15        | CS/Ctx    | Remission |
|               | 32          | F   | 20        | CS/CTX/MG | Remission |
| Mondonca JA, et al ** | 12 | F   | NA        | CS/AZA    | Remission |
|               | 69          | F   | 27        | CS/HQ/AZA | Remission |
| Kudo N, et al ** | 20          | F   | 9         | CS        | Remission |
|               | 22          | F   | 9         | Cholecystectomy/CS/HQ | Remission |
| Choi YJ, et al ** | 26          | F   | 10        | Cholecystectomy/CS/MMF | Remission |
| Obreja EI, et al ** | 24 | F   | 29        | CS/HQ    | Remission |

A2A = azathioprine, CS = corticosteroids, CSA = cyclosporin A, CTX = cyclophosphamide, HQ = hydroxychloroquine, IVG = intravenous immunoglobulin, MMF = mycophenolate mofetil, NA = not available, SLEDAI-2k = SLE Disease Activity Index 2000.

The diagnosis of AAC was based on the clinical manifestations, ultrasonography, CT, and hepatobiliary iminodiacetic acid scans. In our patient, abdominal ultrasonography and CT showed an inﬂamed gallbladder with thickened walls and pericholecystic ﬂuid without gallstones.

Although the pathogenesis of SLE-associated AAC is still unknown, vasculitis, thrombosis, and mesenteric inﬂammatory veno-occlusive disease (MIVOD), and serositis could be the pathogenesis. Vasculitis is considered the most common pathogenesis of SLE-associated AAC. Arteritis and venulitis in the gallbladder may be caused by the aggravation of SLE. The deposition of immune complexes in the blood vessel walls may lead to vasculitis of the target organ. Thrombosis may be observed in SLE patients with antiphospholipid antibodies. This is characterized histologically by multiple thrombi and no evidence of vasculitis. MIVOD is another rare cause of AAC in patients with SLE. This type of vasculitis completely involves the mesenteric veins or their branches and sparing arteries. The main inﬂammatory cells are lymphocytes with occasional granulomatous inﬂammation, but the etiology of MIVOD is unclear.

Although the gallbladder lacks serosa on the surface attached to the liver, serositis may rarely cause cholecystitis. In our case, intestinal ischemia was not detected on abdominal CT. Although the antiphospholipid antibody test was positive and there were no pathologic ﬁndings, vasculitis was considered as the main pathogenesis for this case because of the rapid improvement with corticosteroids.

There are only a few studies on initial manifestation as AAC in SLE. Usually, AAC is a severe disease flare in patients who are identiﬁed to have SLE. AAC is a severe disease flare in patients who are identiﬁed to have SLE. We searched PubMed on cases related to SLE-associated AAC, published after the year 2000, using the phrase “systemic lupus erythematosus and acute acalculous cholecystitis.” We found only 7 case reports and 10 patients (Table 1). All patients were women, and their average age was 34.9 years. The mean SLE Disease Activity Index 2000 was 13.7. Almost all patients were treated with high-dose corticosteroids, except 2 patients who required cholecystectomy. All patients were successfully treated.

The treatment of SLE associated with AAC has been controversial. AAC has high morbidity and mortality, and is difﬁcult to diagnose based on clinical and laboratory ﬁndings alone. Because of the high morbidity associated with AAC, cholecystectomy has been considered in the past. However,
corticosteroid therapy has been successfully used as the initial treatment.\[2,7,16–18\] Hydroxychloroquine allows the reduction of the dosage of corticosteroids and may reduce the risk of flares, organ damage. Most of patients were in remission after treatment without recurrence. However, there was also a case requiring subsequent cholecystectomy among previously reported cases treated with corticosteroids.\[18\] The patient’s general condition and risk factors are important in the medical or surgical treatment decisions. In our case, because the patient was stable and had no risk factors for AAC complications, we considered high-dose corticosteroid with hydroxychloroquine as the initial treatment for SLE-associated AAC. High-dose corticosteroids play a role in immune suppression and anti-inflammation for severe disease flare or inflammation of SLE. This was a case of a patient who presented with AAC as the initial manifestation of SLE, who was treated successfully with high-dose corticosteroids and hydroxychloroquine. Although AAC is extremely rare as the initial manifestation of SLE, it is important to consider AAC as an initial manifestation or severe flare of SLE. As the first treatment for SLE associated AAC, high-dose corticosteroids should be used depending on the patient’s general condition and risk factors.

Author contributions
Conceptualization: Jeonghun Lee, Young Joo Lee.
Investigation: Youngsun Kim.
Project administration: Jeonghun Lee, Young Joo Lee.
Resources: Jeonghun Lee, Young Joo Lee.
Software: Jeonghun Lee, Young Joo Lee.
Supervision: Youngsun Kim.
Writing – original draft: Youngsun Kim, Jeonghun Lee, Young Joo Lee.
Writing – review & editing: Youngsun Kim.

References
[1] Huffman JL, Schenker S. Acute acalculous cholecystitis: a review. Clin Gastroenterol Hepatol 2010;8:15–22.
[2] Xu X, Li B, Zheng C. Hepatobiliary and pancreatic: acute acalculous cholecystitis in systemic lupus erythematosus, successfully treated with corticosteroid. J Gastroenterol Hepatol 2016;31:1673.
[3] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
[4] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400–12.
[5] Adamchou C, Nikolopoulos D, Genitsaridi I, et al. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 2020;79:232–41.
[6] Richer O, Ulinski T, Lemelle I, et al. Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis 2007;66:174–8.
[7] Yang H, Bian S, Xu D, et al. Acute acalculous cholecystitis in patients with systemic lupus erythematosus: a unique form of disease flare. Lupus 2017;26:1101–5.
[8] Mirvis SE, Vannight JR, Nelson AW, et al. The diagnosis of acute acalculous cholecystitis: a comparison of sonography, scintigraphy, and CT. AJR Am J Roentgenol 1986;147:1171–5.
[9] Swanepeol CR, Floyd A, Allison H, et al. Acute acalculous cholecystitis complicating systemic lupus erythematosus: case report and review. Br Med J (Clin Res Ed) 1983;286:251–2.
[10] Bando H, Kobayashi S, Matsumoto T, et al. Acute acalculous cholecystitis induced by mesenteric inflammatory veno-occlusive disease (MIVOD) in systemic lupus erythematosus. Clin Rheumatol 2003;22:447–9.
[11] Basiratnia M, Vasei M, Bahador A, et al. Acute acalculous cholecystitis in a child with systemic lupus erythematosus. Pediatr Nephrol 2006;21:873–6.
[12] Mendonca JA, Marques-Neto JF, Prando P, Appenzeller S. Acute acalculous cholecystitis in juvenile systemic lupus erythematosus. Lupus 2009;18:561–3.
[13] Manuel V, Pedro GM, Cordeiro LB, et al. Acute acalculous cholecystitis in systemic lupus erythematosus: a rare initial manifestation. Rev Bras Reumatol Engl Ed 2016;56:181–4.
[14] Kudo N, Takaoka H, Shimomura T, Suzukioma H, Fujiyama S. Systemic lupus erythematosus-associated acute acalculous cholecystitis successfully treated by a corticosteroid combined with azathioprine. Intern Med 2019;58:2879–85.
[15] Treinen C, Lomelin D, Krause C, Goede M, Oleynikov D. Acute acalculous cholecystitis in the critically ill: risk factors and surgical strategies. Langenbecks Arch Surg 2015;400:421–7.
[16] Shin SJ, Na KS, Jung SS, et al. Acute acalculous cholecystitis associated with systemic lupus erythematosus with Sjogren’s syndrome. Korean J Intern Med 2002;17:61–4.
[17] Choi YJ, Yoon HY, Jang SA, et al. A case of systemic lupus erythematosus initially presented with acute acalculous cholecystitis, J Rheum Dis 2014;21:140–2.
[18] Liu W, Chen W, He X, Qu Q, Hong T, Li B. Successful treatment using corticosteroid combined antibiotic for acute acalculous cholecystitis patients with systemic lupus erythematosus. Medicine (Baltimore) 2017;96:e7478.